[Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia].
OBJECTIVE
To report the results of curative and adverse effects of compound huangdai tablet (CHDT) as induction therapy for 193 patients with acute promyelocytic leukemia (APL).


METHODS
CHDT was administered 1.25 g orally three times a day after meal for three days, then the dosage was gradually increased to 7.5 g/d.


RESULTS
One hundred and ninety-three patients achieved complete remission (CR), 78.8% of whom in 30 to 60 days with an average time of 44.3 d. No serious infection, bleeding or DIC occurred during the treatment course. The major adverse effects were gastrointestinal symptoms. There was no change in lanine transaminase, urea, creatinine or electrocardiographic QTc interval in 110 APL patients observed before and after the treatment.


CONCLUSIONS
CHDT therapy is a modality of higher CR rate, good safety and tolerance without bone marrow suppression for APL patients.
Xiang
Yang
Y
Department of Traditional Chinese Medicine & Hematology, 210th Hospital of PLA, Dalian 116021, China.
Wang
Xiao-Bo
XB
Sun
Shu-Jun
SJ
Guo
Ai-Xia
AX
Wei
Ai-Hong
AH
Cheng
Yu-Bin
YB
Huang
Shi-Lin
SL
D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D002675:Child, Preschool; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008517:Phytotherapy / Q000009:adverse effects; D028321:Plant Preparations / Q000009:adverse effects / Q000627:therapeutic use; D016896:Treatment Outcome; D055815:Young Adult
D028321:Plant Preparations